Provided by Tiger Trade Technology Pte. Ltd.

Enveric Biosciences

5.31
-0.2220-4.01%
Volume:51.17K
Turnover:274.47K
Market Cap:3.17M
PE:-0.04
High:5.68
Open:5.61
Low:5.12
Close:5.53
52wk High:96.30
52wk Low:4.55
Shares:597.00K
Float Shares:594.40K
Volume Ratio:0.20
T/O Rate:8.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-126.0499
EPS(LYR):-228.4745
ROE:-262.78%
ROA:-133.22%
PB:0.92
PE(LYR):-0.02

Loading ...

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:43 PM

Reuters
·
Dec 12

Enveric Biosciences Raises $3.1 Million Through Warrant Exercise

Reuters
·
Dec 12

Enveric Biosciences Enacts 1-for-12 Reverse Stock Split

Reuters
·
Dec 12

Crude Oil Moves Lower; Photronics Shares Surge After Q4 Results

Benzinga
·
Dec 11

What Sparked Enveric Biosciences (ENVB) 74% Surge In After-Hours Trading?

Benzinga_recent_news
·
Dec 10

Enveric Biosciences Receives USPTO Notice of Allowance for EVM301 Series Patent Application

Reuters
·
Dec 09

Enveric Biosciences to Present at Sachs Neuroscience Innovation Forum and Biotech Showcase

Reuters
·
Dec 04

Enveric Biosciences Receives Fourth Notice of Allowance for Evm401 Series of Drug Candidates

THOMSON REUTERS
·
Nov 26

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series Patent Application

Reuters
·
Nov 26

Enveric Biosciences Regains Nasdaq Compliance

TIPRANKS
·
Nov 15

Enveric Biosciences Q3 EPS $(10.81) Up From $(43.10) YoY

Benzinga
·
Nov 15

Enveric Biosciences posts Q3 net loss of $3.4 million

Reuters
·
Nov 15

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

THOMSON REUTERS
·
Nov 15

Enveric Biosciences trading halted, news pending

TIPRANKS
·
Oct 28

Enveric Biosciences Announces 1-for-12 Reverse Stock Split

Reuters
·
Oct 23

BRIEF-Enveric Biosciences Announces Reverse Stock Split

Reuters
·
Oct 23

Enveric Biosciences Secures 23rd U.S. Patent for Novel Neuroplastogenic Compounds Targeting Mental Health Disorders

Reuters
·
Oct 16

Enveric hires firm to contest post-grant review petition filed by Gilgamesh

TIPRANKS
·
Oct 15

Enveric Biosciences Hires Ip Powerhouse to Defend Its U.S. Patent With Claims Relevant to Bretisilocin, Recently Acquired by Abbvie in $1.2 Billion Deal

THOMSON REUTERS
·
Oct 15

Enveric Biosciences to Explore and Negotiate Potential Digital Asset Treasury Strategy Opportunities to Support Long-Term Growth

Reuters
·
Oct 14